Jefferies analyst David Windley sees FDA approvals of GLP-1s for obesity treatment as a huge opportunity for the manufacturing supply chain. He also notes high rivalry in the injectable fill/finish market. Windley upgraded West Pharmaceutical to Buy, raising its price target by 66% to $536, citing its global footprint and capacity to meet growing GLP-1s demand.